Sex: M
Vaccine: COVID19
Symptoms: Respiratory viral panel, White blood cell count
Clinical narrative: BNT162b2 mRNA vaccine related pulmonary eosinophilia; This is a literature report.  A 73-year-old male patient received BNT162b2 (BNT162B2), as dose 1, single (Batch/Lot number: unknown) and as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Non-smoker" (unspecified if ongoing); "nonproductive cough" (unspecified if ongoing); "wheezing" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: PULMONARY EOSINOPHILIA (hospitalization, medically significant), 1 week after the suspect product(s) administration, outcome "unknown", described as "BNT162b2 mRNA vaccine related pulmonary eosinophilia". The patient underwent the following laboratory tests and procedures: Antibody test: weakly positive, notes: (1:4 titer); Antineutrophil cytoplasmic antibody: Normal; Antinuclear antibody: Normal; Aspergillus test: Negative; Biopsy: revealed organizing pneumonia with mixed, notes: mixed inflammatory infiltrate; Blood creatinine: elevated; Blood immunoglobulin E: normal; Bronchoalveolar lavage: 432, notes: Unit: cells/L revealed elevated WBC with neutrophilic predominance (85%); Computerised tomogram thorax: unremarkable; revealed a 2 cm rounded ground-glass opacity in, notes: the right upper lobe; Eosinophil count: 580, notes: Unit: cells/L eosinophilia at 5%; 6814, notes: marked eosinophilia at 29.5; FEV1/FVC ratio: 76 %; Fibrin D dimer: negative; Forced expiratory volume: 2.80 L, notes: (88% predicted); Forced vital capacity: 3.67 L, notes: 90% PREDICTED; anti-CCP: normal; negative; normal; RES-afebrile and audibly wheezing with a, notes: RES-afebrile and audibly wheezing  prolonged expiratory phase; normal; negative; Oxygen saturation: Unknown resul; 93 %, notes: tachypneic on 4LPM supplemental oxygen; Procalcitonin: negative; negative; Pulmonary function test: normal; Red blood cell sedimentation rate: negative; Respiratory viral panel: negative; White blood cell count: 85 %, notes: revealed elevated WBC with neutrophilic; White blood cell count: 13,200, notes: units as ml leukocytosis; 23100, notes: leukocytosis Unit: /mL. Therapeutic measures were taken as a result of pulmonary eosinophilia.  No follow-up attempts are possible. No further information is expected.; Sender's Comments: As there is limited information in the case provided, the causal association between the reported event: "Pulmonary eosinophilia" and the suspect drug BNT162B2 cannot be excluded. The case will be reassessed once new information is available.   The impact of this report on the benefit/risk profile of the Pfizer drug is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees and Investigators, as appropriate.,Linked Report(s) : US-PFIZER INC-202201210157 Same article/patient/drug and different event;